Greenberg R N, Saeed A M, Kennedy D J, McMillian R
Antimicrob Agents Chemother. 1987 Apr;31(4):610-1. doi: 10.1128/AAC.31.4.610.
The implantable Infusaid drug pump model 100 (Shiley Infusaid, Norwood, Mass.) is undergoing trials as a drug delivery system in the treatment of osteomyelitis. This study evaluated the stability of vancomycin (1 mg/ml) incubated at 37 degrees C for 4 weeks in the pump. Both bioassay and high-pressure liquid chromatography data demonstrated a loss of at least 38% of activity over 4 weeks and colloidal precipitation of vancomycin in the pump at the end of the experiment. This study suggests that vancomycin is not stable enough for use in the Infusaid drug pump model 100.
可植入式Infusaid 100型药物泵(马萨诸塞州诺伍德市的Shiley Infusaid公司生产)正在作为一种药物输送系统用于治疗骨髓炎的试验。本研究评估了万古霉素(1毫克/毫升)在37摄氏度下于该泵中孵育4周后的稳定性。生物测定和高压液相色谱数据均表明,4周内活性损失至少38%,且实验结束时泵内出现万古霉素胶体沉淀。本研究提示,万古霉素在Infusaid 100型药物泵中使用时稳定性不足。